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Abstract
Background: The role of pro-inflammatory lipids in systemic immune activation in HIV infection remains largely
unknown. We hypothesized that HIV-1-infected persons on antiretroviral therapy would have pro-inflammatory
high density lipoprotein (HDL), and that an apoA-1 mimetic peptide might reverse the inflammatory properties of
HDL in these persons.
Methods: Plasma was obtained from 10 HIV-1-infected individuals on combination antiretroviral therapy with
suppressed viremia and was incubated with the apoA-I mimetic peptide L-4F or sham-treated prior to isolation of
HDL. The HDL that was isolated from each sample was tested for its ability to inhibit LDL-induced MCP-1
production in cultures of human aortic endothelial cells.
Results: We found in a small pilot study of HIV-1-infected individuals with suppressed viremia on combination
antiretroviral therapy that oxidative stress and inflammation in HIV-1 are associated with a marked reduction of
HDL antioxidant/anti-inflammatory activities. In vitro, these abnormalities were significantly improved by treatment
with the apoA-1 mimetic peptide, 4F.
Conclusions: These preliminary observations suggest that the anti-inflammatory properties of HDL are defective in
HIV-1-infected persons despite treatment that is considered to be virologically successful.
Findings
With improved antiretroviral therapies and survival
among patients with HIV-1, cardiovascular disease
(CVD) has become an increasingly important cause of
morbidity and mortality [1]. The magnitude of the
increased CVD risk among persons with HIV-1 infection
is unclear, however, as are the relative contributions of
viremia, immune activation, antiretroviral therapy
(ART), conventional cardiovascular risk factors (such as
increasing age and hypertension), and changes in sys-
temic inflammation [1]. Understanding the relative con-
tributions of host, virus, and antiretroviral therapy to
risk of CVD in HIV-1 infection will aid in the develop-
ment of strategies for prevention and treatment.
Inflammation has increasingly been recognized to be
pivotal in the initiation and perpetuation of arterial
injury leading to atherosclerosis and its complications
[2]. Pro-inflammatory high density lipoprotein (HDL)
may play a role in this process; higher serum levels of
pro-inflammatory HDL are associated with the increased
rates of CVD in certain chronic inflammatory conditions
such as rheumatoid arthritis, systemic lupus erythemato-
sus, and type II diabetes mellitus [3]. While immune
activation is a hallmark of HIV-1 infection, it is not
known if HIV-1 infection affects levels of pro-inflamma-
tory HDL, or if increases in HDL cholesterol (HDL-C)
observed after initiation of ART in longitudinal studies
are neutral, atheroprotective or atherogenic in nature
[2,4-8].
With regards to pro-inflammatory lipids, apoA-1
mimetic peptides have been shown to remove oxidation
products from lipoproteins and cell membranes and
restore structure and function of low density lipoprotein
(LDL) and HDL in a wide range of experimental inflam-
matory conditions in animals [9]. In view of the sys-
temic immune activation that is not entirely reversed
despite effective ART [9,10] and which could therefore
be conducive to generating pro-inflammatory lipids, we
hypothesized that HIV-1-infected persons on ART
would have pro-inflammatory HDL, and that an apoA-1
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ties of HDL in these persons.
Materials and methods
Patients
To test this hypothesis, plasma was obtained from 10
HIV-1-infected individuals on combination antiretroviral
therapy with suppressed viremia (below 50 copies of
RNA/ml). Informed consent was obtained from all
subjects.
Determination of proinflammatory HDL
Plasma was incubated with the apoA-I mimetic peptide
L-4F at a concentration of 1 μg/mL for 15 minutes at
37°C, or sham-treated prior to FPLC fractionation.
HDL-containing FPLC fractions were tested for their
ability to inhibit LDL-induced MCP-1 production in cul-
tures of human aortic endothelial cells as previously
described [9]. Results were normalized as a ratio to the
effect of control LDL without HDL to yield the HDL
inflammatory index (HII). More specifically HII is calcu-
lated from the ratio LDL-induced monocyte chemotactic
activity (as determined by MCP-1 production in cultures
of human aortic endothelial cells) in the presence of
HDL/LDL-induced monocyte chemotactic activity in
cultures of human aortic endothelial cells in the absence
of HDL [9]. Data were analyzed with Student’st - t e s t
using SPSS 13.5 software (Chicago, IL, USA) and
expressed as mean ± SD; P-values less than 0.05 were
considered significant.
Results
All subjects were men with an average age of 43 ± 14 years
(± SD, range 21 - 63) on combination ART. Viral load and
CD4
+ T cell counts were available on nine subjects (Table 1);
these had plasma HIV-1 RNA values < 50 copies/mL and
mean blood CD4
+ T cell counts of 595 ± 166 cells/mm
3
(range 367 - 966). Mean HII values for HDL in the sham
treated plasma were 2.16 ± 0.63 (range 1.01 - 2.73) while
mean HII values for HDL in the L-4F treated plasma were
significantly lower (p < 0.0001) at 0.89 ± 0.16 (range 0.64 -
1.19). These values were compared to previously reported
mean values from healthy controls (0.43 ± 0.05 and 0.20 ±
0.04 for sham and 4F treatment respectively (Figure 1) [9].
Thus, high-density lipoprotein isolated from plasma of per-
sons with ART treated HIV-1 infection was highly pro-
inflammatory, and was markedly less pro-inflammatory after
treatment of plasma with 4F in vitro (Figure 1). Both the
high baseline HII and reduction of the inflammatory index
after 4F treatment were observed in all 10 samples, suggest-
ing an overall pro-inflammatory lipid profile that was at least
partially reversible by 4F.
Discussion
Classically, HDL is believed to play an important role in
mitigating oxidative stress and inflammation by uptake,
processing and disposal of oxidized lipids [2,11]. How-
ever, systemic inflammation has been shown to lower
this antioxidant and anti-inflammatory activity by trans-
forming HDL to a pro-oxidant, pro-inflammatory acute-
phase HDL that enhances the tendency of LDL to induce
monocyte chemotaxis [2]. It has been demonstrated that
mice that are genetically susceptible to develop athero-
sclerosis have augmented pro-inflammatory HDL [9,11].
HDL, therefore, not only removes excess LDL-derived
cholesterol from peripheral tissues, but also has a major
role in mitigating LDL-induced inflammation.
In our small cohort, all HIV-1-infected persons showed
a marked reduction of HDL anti-inflammatory activity as
evidenced by impaired HDL mediated inhibition of LDL-
induced monocyte chemotactic activity. The observed
defect cannot be attributed to low plasma HDL level in
Table 1 Characteristics of the HIV-1-infected study participants
Subject Age Sex CD4 count
(cells/mm
3)
VL (RNA/ml) TC (mg/dl) HDL (mg/dl) LDL (mg/dl) TG (mg/dl) HII (sham) HII (L-4F) ART
1 25 M 367 < 50 135 51 66 91 2.45 0.75 AZV, RTV, TDF, FTC
2 NA M NA NA NA NA NA NA 2.69 1.19 NA
3 57 M 499 < 50 159 31 77 254 1.01 0.69 EFV, ABC, 3TC
4 44 M 540 < 50 NA NA NA NA 2.73 0.96 TDF, FTC, RTV, FPV
5 44 M 540 < 50 286 26 212 240 2.55 0.93 TDF, FTC, AZV, RTV
6 46 M 571 < 50 184 52 108 121 1.82 0.89 NA
7 47 M 966 < 50 176 52 122 100 2.61 0.86 TDF, FTC, NVP
8 31 M 553 < 50 205 76* 109 98 1.24 0.64 EFV, FTC, TDF
9 21 M 712 < 50 169 64* 93 58 1.95 1.00 EFV, FTC, TDF
10 62 M 605 < 50 167 44 88 176 2.57 1.00 LPV, RTV, 3TC ETV
Abbreviations: AZV: Atazanavir; ABC: Abacavir; ART: Antiretroviral therapy; ETV: Etravirine; Efavirenz (EFV), FTC: Emtricitabine, FPV: Fosamprenavir; HDL: High
Density Lipoprotein; HII; HDL Inflammatory Index; 3TC: Lamivudine; LPV: lopinavir; LDL: Low Density Lipoprotein; M: Male; NVP: Nevirapine; NA: Not available; TDF:
Tenofovir; TC: Total Cholesterol; TG: Triglycerides; RTV: Ritonavir; VL: Viral Load
*:Samples were collected when patients were non-fasting.
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assayed; thus the observed HDL dysfunction must be due
primarily to qualitative abnormalities. Oxidative stress
and inflammation are nearly constant features of HIV-1
infection and the prevailing inflammatory state likely
contributes to the observed reduction of HDL anti-
inflammatory function in this population. This could lead
to a vicious cycle in which the underlying inflammation
and oxidative stress induce HDL dysfunction, which
results in further inflammation.
Treatment of plasma samples from the HIV-1-infected
subjects with the potent apoA-1 mimetic peptide 4F
results in a marked increase in HDL anti-inflammatory
activity. 4F is an 18-amino acid apoA-1 mimetic peptide,
and its anti-inflammatory effects are mediated by its abil-
ity to preferentially remove oxidation products from lipo-
proteins and cell membranes, thereby restoring HDL and
LDL function and structure, improving cell function, and
attenuating inflammation [11]. ApoA-1 mimetic peptides
have been shown to reduce atherosclerosis and attenuate
inflammation in experimental animals without signifi-
cantly changing plasma lipid levels [11]. 4F treatment in
this study generally failed to return the pro-inflammatory
activity of HDL to the low levels that we have previously
reported in healthy controls [9].
These preliminary observations suggest that the
anti-inflammatory properties of HDL are defective in
HIV-1-infected persons despite treatment that is consid-
ered to be virologically successful, and that standard
clinical lipid profile testing may not be an adequate
measurement of the risk for CVD in these individuals.
In this small pilot study we did not assess the possible
association of proinflammatory HDL with other markers
of immune activation and inflammation and the possible
effect of 4F on these markers. An ongoing prospective
study will aim at addressing the possible association of
proinflammatory HDL with other markers of inflamma-
tion, immune activation and progression of athero-
sclerosis in patients with HIV infection. This study will
also evaluate the effect of different types of antiretroviral
treatment regimens versus HIV infection itself on the
HDL inflammatory index.
In conclusion, to our knowledge this is the first
demonstration that HIV-1 infection is associated with a
marked reduction of HDL antioxidant/anti-inflammatory
activities. In vitro, these abnormalities were significantly
improved by treatment with the apoA-1 mimetic pep-
tide, 4F.
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